EP2678025B1 - Vsdl for use in the treatment of acute decompensated congestive heart failure - Google Patents
Vsdl for use in the treatment of acute decompensated congestive heart failure Download PDFInfo
- Publication number
- EP2678025B1 EP2678025B1 EP11815913.6A EP11815913A EP2678025B1 EP 2678025 B1 EP2678025 B1 EP 2678025B1 EP 11815913 A EP11815913 A EP 11815913A EP 2678025 B1 EP2678025 B1 EP 2678025B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- vsdl
- infusion
- subject
- administered
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010007559 Cardiac failure congestive Diseases 0.000 title claims description 44
- 206010019280 Heart failures Diseases 0.000 title claims description 43
- 230000001154 acute effect Effects 0.000 title claims description 7
- 238000011282 treatment Methods 0.000 title description 19
- 108010090012 atrial natriuretic factor prohormone (31-67) Proteins 0.000 claims description 104
- 102400001284 Vessel dilator Human genes 0.000 claims description 101
- 238000001802 infusion Methods 0.000 claims description 52
- 230000037396 body weight Effects 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 description 17
- 230000001684 chronic effect Effects 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 230000036772 blood pressure Effects 0.000 description 13
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 12
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 12
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 11
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 11
- 239000002934 diuretic Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 230000036581 peripheral resistance Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 230000009286 beneficial effect Effects 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 230000000747 cardiac effect Effects 0.000 description 7
- 206010011376 Crepitations Diseases 0.000 description 6
- 206010037368 Pulmonary congestion Diseases 0.000 description 6
- 206010037423 Pulmonary oedema Diseases 0.000 description 6
- 208000037656 Respiratory Sounds Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000001435 haemodynamic effect Effects 0.000 description 6
- 230000001452 natriuretic effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000000059 Dyspnea Diseases 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000001882 diuretic effect Effects 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 102400001263 NT-proBNP Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000004872 arterial blood pressure Effects 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 230000002861 ventricular Effects 0.000 description 4
- 206010013969 Dyspnoea at rest Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000288140 Gruiformes Species 0.000 description 3
- 241000282560 Macaca mulatta Species 0.000 description 3
- 108020001621 Natriuretic Peptide Proteins 0.000 description 3
- 102000004571 Natriuretic peptide Human genes 0.000 description 3
- 102100036836 Natriuretic peptides B Human genes 0.000 description 3
- 101710187802 Natriuretic peptides B Proteins 0.000 description 3
- 241000282405 Pongo abelii Species 0.000 description 3
- 206010071436 Systolic dysfunction Diseases 0.000 description 3
- 102000004987 Troponin T Human genes 0.000 description 3
- 108090001108 Troponin T Proteins 0.000 description 3
- 238000002583 angiography Methods 0.000 description 3
- 238000013184 cardiac magnetic resonance imaging Methods 0.000 description 3
- 238000011976 chest X-ray Methods 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000692 natriuretic peptide Substances 0.000 description 3
- 230000036593 pulmonary vascular resistance Effects 0.000 description 3
- 206010037833 rales Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000036387 respiratory rate Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010043089 tachypnoea Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 230000000304 vasodilatating effect Effects 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010062237 Renal impairment Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 208000028831 congenital heart disease Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010002915 Aortic valve incompetence Diseases 0.000 description 1
- 241000856922 Arctia caja Species 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 241000777300 Congiopodidae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000023281 Fallot tetralogy Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031309 Hypertrophic Familial Cardiomyopathy Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 208000035478 Interatrial communication Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010027727 Mitral valve incompetence Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000283080 Proboscidea <mammal> Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 201000003005 Tetralogy of Fallot Diseases 0.000 description 1
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 1
- 101800001899 Vessel dilator Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 201000002064 aortic valve insufficiency Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 208000013914 atrial heart septal defect Diseases 0.000 description 1
- 206010003664 atrial septal defect Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 201000010552 hypertrophic cardiomyopathy 1 Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000011294 monotherapeutic Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 208000003278 patent ductus arteriosus Diseases 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 208000007340 tricuspid atresia Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 201000003130 ventricular septal defect Diseases 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Definitions
- the present invention relates to vessel dilator for use in the treatment of congestive heart failure (CHF) in a subject.
- the invention relates to vessel dilator for use in the treatment of the indication known as acute decompensated congestive heart failure (ADCHF).
- CHF congestive heart failure
- ADCHF acute decompensated congestive heart failure
- CHF is a major health problem affecting over 23 million people worldwide causing significant morbidity and mortality 1 .
- CHF occurs when the heart inadequately pumps oxygenated blood to the rest of the body, resulting in the retention of fluid (oedema), shortness of breath (dyspnea) and lethargy. Often, it is also accompanied by renal failure as the kidneys strain to maintain glomerular filtration in an attempt to excrete the build up of excess fluids 2 .
- CHF may be caused by one or a combination of factors including: weakened heart muscle, damaged heart valves, blocked blood vessels supplying the heart muscle (ie cardiac arteries), high blood pressure leading to a thickening of the heart muscle (ie left ventricular hypertrophy), congenital heart disease, prolonged arrhythmias, infections, and life style factors such as smoking, obesity and alcohol or drug (eg cocaine) consumption which can, for example, be the cause of long term, uncontrolled high blood pressure (hypertension) that may damage the heart muscle and blood vessels. If steps are not taken to treat CHF when it becomes apparent and/or modify patient life style, the CHF may become a long term (ie chronic) condition.
- factors including: weakened heart muscle, damaged heart valves, blocked blood vessels supplying the heart muscle (ie cardiac arteries), high blood pressure leading to a thickening of the heart muscle (ie left ventricular hypertrophy), congenital heart disease, prolonged arrhythmias, infections, and life style factors such as smoking, obesity and alcohol or drug (eg cocaine
- VSDL Vessel dilator
- aa 37 amino acid
- ADP atrial natriuretic peptide
- the main biological activity of VSDL is to regulate blood pressure and maintain plasma volume in healthy individuals by mediating natriuretic, diuretic and haemodynamic effects 4 .
- Preliminary studies on VSDL's effect in CHF have been conducted via both preclinical and human clinical studies 8, 9 .
- VSDL enhanced sodium excretion 3- to 4-fold in CHF patients ( P ⁇ 0.01), and was still significantly ( P ⁇ 0.01) elevated 3 hours after infusion.
- VSDL could: decrease systemic vascular resistance (SVR) (24%); decrease pulmonary vascular resistance (PVR) (25%); decrease pulmonary capillary wedge pressure (PCWP) (33%); decrease central venous pressure (CVP) (27%); increase cardiac output (CO) (34%); increase cardiac index (CI) (35%); and increase stroke volume index (SVI) (24%); without significantly affecting heart rate or pulmonary artery pressure in the CHF patients.
- SVR systemic vascular resistance
- PVR pulmonary vascular resistance
- PCWP decrease pulmonary capillary wedge pressure
- CVP central venous pressure
- CO increase cardiac output
- CI cardiac index
- SVI stroke volume index
- VSDL promotes the synthesis of the renal protective agent, prostaglandin E 2 (PGE 2 ), and can increase circulating PGE 2 8-fold compared to basal levels 11 .
- PGE 2 also benefits CHF patients by decreasing mean arterial pressure and total peripheral resistance while increasing stroke volume index and cardiac output.
- VSDL circulates in healthy humans at significantly higher basal levels than other atrial natriuretic peptides, including ANP and B-type natriuretic peptide (BNP), where the circulating concentration of VSDL is 17-fold and 48-fold higher than ANP and BNP respectively. Hitherto the studies described herein, this was believed to owe, in part, to VSDL possessing a significantly longer circulatory t 1 ⁇ 2 of ⁇ 120 minutes and biological t 1 ⁇ 2 of ⁇ >6 hours. In comparison, it has been reported that BNP has a circulating t 1 ⁇ 2 of ⁇ 3.1 minutes and biological t 1 ⁇ 2 of ⁇ 1 ⁇ 2 hour 4, 6-9, 12 and 13 .
- VSDL administration to patients with chronic CHF or ADCHF as a safe and effective treatment for mediating beneficial haemodynamic effects with additional beneficial natriuretic, diuretic and renal effects, whilst regulating plasma volume and blood pressure (BP) within clinically acceptable ranges and without seriously adverse side effects. It is also anticipated that such VSDL treatment may reduce hospitalisation time and readmission rates for chronic CHF and ADCHF patients. Further, the present applicant has found that effective treatment of chronic CHF and ADCHF patients with VSDL can be achieved with doses that are substantially lower than expected.
- the present invention is directed to vessel dilator (VSDL) for use in treating acute decompensated congestive heart failure (ADCHF) in a subject.
- VSDL vessel dilator
- ADCHF acute decompensated congestive heart failure
- the VSDL is administered to the subject at an effective amount by infusion at a rate of 1 to 400 ng per kg subject body weight per minute (ng/kg/min).
- the subject may be a non-human primate or other mammalsuch as livestock (including race horses), an exotic animal (e.g. tigers and elephants) or a companion animals (e.g. dogs and cats), however typically the subject will be a human, in which case, VSDL is most preferably used for treating ADCHF characterised by:
- the term "effective amount" as used herein refers to an amount of the VSDL that will elicit a desired biological or therapeutic response in the subject (e.g. beneficial haemodynamic effects with, preferably, additional beneficial natriuretic, diuretic and renal effects whilst regulating plasma volume and blood pressure (BP) within clinically acceptable ranges).
- the effective amount will, however, typically be in the range of 0.1 to 75 ⁇ g/kg/day.
- the effective amount of VSDL is preferably administered by infusion (preferably, by intravenous ( iv ) or subcutaneous ( sc ) infusion) as a single dose per day or, otherwise, across multiple times per day (eg 2 to 4 times per day).
- the effective amount of VSDL may, for example, be administered by infusion at a rate of ⁇ 100 ng/kg/min, and preferably, at a rate of about ⁇ 75 ng/kg/min, more preferably at a rate of about ⁇ 50 ng/kg/min or ⁇ 30 ng/kg/min, still more preferably at a rate of about ⁇ 25 ng/kg/min, even still more preferably ⁇ 20 ng/kg/min and, and yet still more preferably, at a rate of about ⁇ 15 ng/kg/min.
- the present invention relates to vessel dilator (VSDL), a peptide derived from atrial natriuretic peptide (ANP) prohormone, for use in treating ADCHF in a subject.
- VSDL vessel dilator
- NBP atrial natriuretic peptide
- the VSDL is administered to a subject at an effective amount, typically in the range of 0.1 to 75 ⁇ g/kg/day.
- the VSDL is administered to the subject an effective amount by infusion at a rate of 1 to 400 ng per kg subject body weight per minute (ng/kg/min).
- the effective amount of VSDL is in the range of 0.1 to 75 ⁇ g/kg/day, more preferably in the range of about 0.1 to 25 ⁇ g/kg/day, still more preferably in the range of about 0.1 to 20 ⁇ g/kg/day or about 0.1 to 5 ⁇ g/kg/day, and even still more preferably, in the range of about 0.1 to 3.5 ⁇ g/kg/day or 0.1 to 1.5 ⁇ g/kg/day. Most preferably, the effective amount that is administered to the subject will be about 0.75 ⁇ g/kg/day.
- the effective amount of VSDL may, for example, be administered by infusion at a rate of ⁇ 100 ng/kg/min, and preferably, at a rate of about ⁇ 75 ng/kg/min, more preferably at a rate of about ⁇ 50 ng/kg/min or ⁇ 30 ng/kg/min, still more preferably at a rate of about ⁇ 25 ng/kg/min, even still more preferably ⁇ 20 ng/kg/min and, and yet still more preferably, at a rate of about ⁇ 15 ng/kg/min. Most preferably, the effective amount is infused at a rate in the range of 1 to 15 ng/kg/min, most preferably at a rate of about 12.5 ng/kg/min.
- the effective amount of VSDL may be infused (preferably, by intravenous ( iv ) or subcutaneous ( sc ) infusion) as a single dose per day or, otherwise, across multiple times per day (e.g. as three equal separate doses at 0 hours, 6 hours and 12 hours).
- iv intravenous
- sc subcutaneous
- a single dose (or each dose of a multidose regimen), will be infused over a period of about 60 minutes.
- the rate of the infusion is at a preferred rate of ⁇ 75 ng/kg/min, it is considered that a single dose over a period of about 60 minutes will provide an effective daily dose (ie of ⁇ 4.5 ⁇ g/kg/day). Further, where lower infusion rates are employed of 25 ng/kg/min and 12.5 ng/kg/min, it is considered that a single dose over a period of 60 minutes will provide an effective daily dose of ⁇ 1.5 ⁇ g/kg/day and ⁇ 0.75 ⁇ g/kg/day, respectively.
- VSDL is used for treating ADCHF with a symptom severity level of NYHA class III or IV.
- VSDL is used for treating ADCHF in a human characterised by:
- VSDL Vessel dilator
- proANP 31-67 a peptide consisting of the amino acids 31-67 of the ANP prohormone.
- the amino acid sequence of the preferred, human, VSDL is as follows:
- VSDL peptides include:
- Peptides derived from ANP prohormone may be produced by any of the standard protein synthesis methods well known to the person skilled in the art or, more preferably, by recombinant techniques involving, for example, the introduction of a polynucleotide molecule encoding the particular peptide into a suitable host cell (eg a host cell selected from bacterial cells such as E. coli , Streptomyces and S .
- a suitable host cell eg a host cell selected from bacterial cells such as E. coli , Streptomyces and S .
- fungal cells such as yeast cells
- insect cells such as Drosophila S2 and Spodoptera Sf9 cells
- animal cells such as Chinese hamster ovary (CHO), monkey kidney (COS) cells and human embryonic kidney 293 (HEK 293) cells; and plant cells) and culturing the cell under conditions suitable for the expression of the particular peptide.
- CHO Chinese hamster ovary
- COS monkey kidney
- HEK 293 human embryonic kidney 293
- the VSDL peptide derived from ANP prohormone will be administered as a composition consisting of a simple solution or suspension of the peptide in a pharmaceutically-acceptable carrier.
- a carrier molecule eg a carrier protein or fusion partner such as human serum albumin (HSA) or a polysaccharide (eg Dextran) or polyether (eg polyethylene glycol)
- HSA human serum albumin
- a polysaccharide eg Dextran
- polyether eg polyethylene glycol
- pharmaceutically-acceptable carrier refers to any pharmaceutically- or veterinary-acceptable solvent, suspending agent or vehicle for delivering the peptide derived from ANP prohormone or mimetic thereof to the subject.
- the carrier may include one or more pharmaceutical additives of a type appropriate to, for example, iv administration (eg excipients, preservatives, stabilisers etc).
- the VSDL peptide derived from ANP prohormone may be administered to the subject in a combination therapy.
- the administration of VSDL should not cause clinically significant hypotension, they can be vasodilatory and, therefore, it is preferred that any combination therapy avoids other vasodilatory agents which may cause a synergetic blood pressure lowering. For that reason, the present invention may not be suitable for the treatment of subjects already using vasodilatory agents.
- VSDL peptide by infusion is, preferably, achieved intravenously (iv ) (which is particularly suitable in the hospital setting) or subcutaneously (sc ) (which is suitable for both hospitalised patient and out-of-hospital administration).
- infusion may be via a standard catheter or implantable drug port (eg a Port-a-Cath®; Smiths Medical MD, Inc., St.
- a drug infusion pump eg implantable drug infusion pumps such as an Alzet® osmotic pump (Durect Corporation, Cupertino CA, United States of America) and a Duros® device (Intarcia Therapeutics, Inc., Hayward CA, United States of America), or a drug infusion pump for subcutaneous ( sc ) administration such as a ParadigmTM device (Medtronic Australasia Pty Ltd, Gladesville NSW, Australia) all of which can provide a controlled release of the peptide) which preferably infuses the peptide at a constant rate.
- a drug infusion pump eg implantable drug infusion pumps such as an Alzet® osmotic pump (Durect Corporation, Cupertino CA, United States of America) and a Duros® device (Intarcia Therapeutics, Inc., Hayward CA, United States of America
- a drug infusion pump for subcutaneous ( sc ) administration such as a ParadigmTM device (Medtronic Australasia Pt
- an implantable drug port or drug infusion pump will be particularly well suited for long term treatment.
- the peptide will be infused at a constant rate, however, in some cases it may be desirable to employ a drug infusion pump employing a feedback control mechanism (eg a feedback linked to measurement of oedema (in the lung) or other surrogate marker) to control release of the peptide.
- a feedback control mechanism eg a feedback linked to measurement of oedema (in the lung) or other surrogate marker
- the VSDL is administered to the subject at an effective amount, wherein said effective amount is in the range of about 0.1 to 20 ⁇ g/kg/day and is administered by infusion, preferably intravenous ( iv ) or subcutaneous ( sc ) infusion, at a rate of ⁇ 50 ng/kg/min.
- infusion preferably intravenous ( iv ) or subcutaneous ( sc ) infusion, at a rate of ⁇ 50 ng/kg/min.
- the VSDL is administered to the subject at an effective amount, wherein said effective amount is in the range of about 0.1 to 1.5 ⁇ g/kg/day and is administered by infusion, preferably intravenous ( iv ) or subcutaneous ( sc ) infusion.
- infusion preferably intravenous ( iv ) or subcutaneous ( sc ) infusion.
- the effective amount and frequency of administration of the peptide for any particular subject may be varied and will depend upon a variety of factors including the activity of the particular peptide that is utilised, the metabolic stability and length of action of the particular peptide, the age, body weight, general health, sex and diet of the particular subject, and the time of administration, rate of excretion, drug combination and severity of the ADCHF being treated.
- This example describes a study to examine whether VSDL administration to ADCHF patients will be safe and induce improvements in haemodynamic parameters, as well as renal, natriuretic and diuretic parameters, whilst regulating plasma volume and BP within clinically acceptable ranges and without seriously adverse side effects.
- VSDL in the form of a white lyophilised powder (synthesised using standard protein synthesis method by Auspep Pty Ltd, Parkville, VIC, Australia), stored in an ultra low freezer (-80°C), was reconstituted in a vial with 10 ml of 0.9% saline (preservative free) and aseptically transferred into a 20 ml syringe (that conects to a patient cannula) before use.
- an iv dose of 12.5 ng/kg/min was infused into test subjects for 60 minutes with a syringe driver (Alaris Asena GS syringe driver; CareFusion Corporation, San Diego, CA, United States of America).
- This "safety dose” was chosen merely to trial the subjects for any adverse effects.
- a dose of 25 ng/kg/min was trialled.
- a trial will be conducted with a dose of 50 ng/kg/min (for 60 minutes).
- CHF chronic CHF or ADCHF (NYHA class III - NYHA class IV) defined as:
- VSDL single dose of VSDL of 12.5 ng/kg/min for 60 minutes (ie single dose regimen) for a daily dose of 0.75 ⁇ g/kg.
- a further subject was trialled with a single dose of VSDL of 25 ng/kg/min for 60 minutes (to achieve a daily dosage of 1.5 ⁇ g/kg).
- Two further subjects are/have been recruited for trials with a single dose of VSDL of 25 ng/kg/min for 60 minutes, along with another subject (in a preliminary trial) for dosing with a single infusion of VSDL of 50 ng/kg/min for 60 minutes (to achieve a dosage of 3 ⁇ g/kg).
- the results will be compared with subjects recruited as a control group and who will receive a standard method of care for the treatment of ADCHF.
- Markers of efficacy were measured at baseline (prior to VSDL infusion), 1 hour (post VSDL infusion), and 24 hours.
- the markers included CI, PCWP, pulmonary arterial wedge pressure (PAWP), BP, SVR and PVR, and were measured using standard methods well known to the person skilled in the art.
- Troponin T, proBNP, CK and CK-MB concentrations were also measured by standard methods.
- dyspnea relief and increased urine flow and volume output.
- CI cardiac index
- PCWP pulmonary capillary wedge pressure
- BP asymptomatic drop in blood pressure
- the subject remained stable during the 24 hours following the infusion.
- This female subject received a single dose of iv VSDL in saline (12.5 ng/kg/min for 60 mins), on 7 October 2010.
- the subject tolerated the infusion well.
- the blood concentration of the CHF marker proBNP decreased 75% during and within the 24 hours following the infusion.
- the subject also remained clinically stable during this period.
- exogenous VSDL infusion 50 ng/kg/min, 100 ng/kg/min and 200 ng/kg/min for 60 minutes to ascertain the approximate amounts of exogenous VSDL required by late NHYA class III - NYHA class IV patients to reinstate homeostasis.
- doses were expected to result in an approximately 2-fold, 4-fold and 8-fold increase in total circulating VSDL, respectively.
- the present applicant had particularly proposed an exogenous dose of VSDL at ⁇ 100 ng/kg/min (for 60 mins) for the treatment of chronic CHF or ADCHF as a safe and effective dosage, since it has been identified that the release rate from the heart of VSDL with physiological stimuli is about 138 ng/kg body weight per minute 16 and similar dosages have been previously observed to cause a marked natriuresis and diuresis in healthy humans 17,18 and, also, improved haemodynamic and renal parameters in persons with stable NYHA class III chronic CHF 10 .
- the molar equivalent of the 100 ng/kg body weight dose (for 60 mins) is 26 pmol/kg body weight (for 60 mins).
- C max was estimated from blood samples of a CHF patient (NYHA class III) taken at 30 mins, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr and 12 hr following infusion, using a proprietary method (CPR Pharma Services Pty Ltd, Thebarton, SA, Australia) involving mass spectroscopy.
- the baseline VSDL concentration ie endogenous level
- predose was estimated from an identical sample taken prior to infusion (ie "predose").
- the baseline VSDL concentration was estimated as 0.024 ng/ml.
- the measured VSDL concentrations in the samples taken at the various time points are shown in Table 3 and Figure 3 .
- a corrected concentration, which accounts for the baseline concentration is also shown; however due to the low level of the baseline concentration, the corrected concentrations vary little from the actual, measured concentrations.
- the C max was therefore 4.376 ng/ml ( ⁇ 4.4 ng/ml) achieved 30 mins (ie T max of 0.5 hr) after infusion. This value was also estimated after 1 hr. There is a slight curve to the measured VSDL concentration profile ( Figure 3 ) indicating that the elimination of VSDL from the blood stream does not clearly follow first order kinetics.
- the LOQ of 0.2 ng/ml gives an estimated half-life (t 1 ⁇ 2 ) of 20 minutes, while using the point just below the LOQ estimates a slightly longer half-life of 25-30 minutes, excluding and including the C max values, respectively.
- the baseline VSDL concentration in blood was estimated as 0.024 ng/ml. This was surprisingly low given previously published reports of endogenous basal levels of circulating VSDL in patients with varying degrees of CHF; for example, a basal VSDL concentration of 3412 ⁇ 546 (SEM) fmol/ml has been reported for CHF NYHA class III patients and 7691 ⁇ 1344 (SEM) fmol/ml for CHF NYHA class IV patients 6 . These values correspond to about 13.23 ng/ml and 29.82 ng/ml. C max for the infused VSDL was achieved at a T max of 0.5 hr.
- t 1 ⁇ 2 of 25-30 mins estimated from this study is much shorter than that previously reported (ie 120 mins). While not wishing to be bound by theory, it is considered that this previously reported t 1 ⁇ 2 of 120 mins may have been the result of inadvertently providing a supramaximal dose.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
- The present invention relates to vessel dilator for use in the treatment of congestive heart failure (CHF) in a subject. In particular, the invention relates to vessel dilator for use in the treatment of the indication known as acute decompensated congestive heart failure (ADCHF).
- CHF is a major health problem affecting over 23 million people worldwide causing significant morbidity and mortality1. CHF occurs when the heart inadequately pumps oxygenated blood to the rest of the body, resulting in the retention of fluid (oedema), shortness of breath (dyspnea) and lethargy. Often, it is also accompanied by renal failure as the kidneys strain to maintain glomerular filtration in an attempt to excrete the build up of excess fluids2. CHF may be caused by one or a combination of factors including: weakened heart muscle, damaged heart valves, blocked blood vessels supplying the heart muscle (ie cardiac arteries), high blood pressure leading to a thickening of the heart muscle (ie left ventricular hypertrophy), congenital heart disease, prolonged arrhythmias, infections, and life style factors such as smoking, obesity and alcohol or drug (eg cocaine) consumption which can, for example, be the cause of long term, uncontrolled high blood pressure (hypertension) that may damage the heart muscle and blood vessels. If steps are not taken to treat CHF when it becomes apparent and/or modify patient life style, the CHF may become a long term (ie chronic) condition. The severity of symptoms of patients with chronic CHF can progress to a level where there is a "marked limitation in activity [and the patient is] comfortable only at rest" as per Class III of the New York Heart Association (NYHA) CHF functional classification. Consequently, patients with chronic CHF that has progressed to NYHA class III can require frequent hospitalisation and/or palliative care. Moreover, while such chronic CHF is generally stable, it may easily decompensate to the often critical state known as acute decompensated congestive heart failure (ADCHF). This can be caused for a variety of reasons including arrhythmias, ischaemia, illness such as pneumonia and poor compliance with diet and medications19.
- In the United States alone, over 1.1 million people are admitted to hospital every year with ADCHF1, 10% of which die in care and 40% of which die within the year. Further, it has been reported that over 6.5 million days of hospitalisation per year in the United States are attributable to ADCHF3. These costs account for almost 50% of the US$34 billion spent each year on heart failure care in the United States. Unfortunately, ADCHF remains as an unmet clinical need, with current monotherapeutic and polytherapeutic treatments being effectively, and efficaciously, limited at alleviating symptoms only.
- Vessel dilator (VSDL) is a naturally occurring 37 amino acid (aa) cardiac peptide consisting of amino acids 31-67 of the 126 aa atrial natriuretic peptide (ANP) prohormone4, 6 and 7. Like other natriuretic peptides, the main biological activity of VSDL is to regulate blood pressure and maintain plasma volume in healthy individuals by mediating natriuretic, diuretic and haemodynamic effects4. Preliminary studies on VSDL's effect in CHF have been conducted via both preclinical and human clinical studies8, 9. One of the first studies exploring the use of synthetic VSDL in a CHF animal model was in normal and compensated aorto-caval (AV) fistula dogs, resulting in similar significant reductions in arterial blood pressure, right atrial pressure and elevations in urinary sodium excretion5. The human studies have involved patients with chronic, but stable, New York Heart Association (NYHA) Class III CHF10, and have shown that VSDL can significantly improve natriuretic, diuretic and haemodynamic parameters without any symptomatic side effects. In particular, it has been shown that VSDL is able to increase urine flow 2- to 13-fold, and urine flow was still increased (P<0.001) 3 hours after the VSDL infusion was halted10. Further, it was found that VSDL enhanced sodium excretion 3- to 4-fold in CHF patients (P<0.01), and was still significantly (P<0.01) elevated 3 hours after infusion. Moreover, it was found that VSDL could: decrease systemic vascular resistance (SVR) (24%); decrease pulmonary vascular resistance (PVR) (25%); decrease pulmonary capillary wedge pressure (PCWP) (33%); decrease central venous pressure (CVP) (27%); increase cardiac output (CO) (34%); increase cardiac index (CI) (35%); and increase stroke volume index (SVI) (24%); without significantly affecting heart rate or pulmonary artery pressure in the CHF patients. In addition, it is also known that VSDL promotes the synthesis of the renal protective agent, prostaglandin E2 (PGE2), and can increase circulating PGE2 8-fold compared to basal levels11. PGE2 also benefits CHF patients by decreasing mean arterial pressure and total peripheral resistance while increasing stroke volume index and cardiac output.
- It has been reported that VSDL circulates in healthy humans at significantly higher basal levels than other atrial natriuretic peptides, including ANP and B-type natriuretic peptide (BNP), where the circulating concentration of VSDL is 17-fold and 48-fold higher than ANP and BNP respectively. Hitherto the studies described herein, this was believed to owe, in part, to VSDL possessing a significantly longer circulatory t½ of ∼120 minutes and biological t½ of ~>6 hours. In comparison, it has been reported that BNP has a circulating t½ of ~3.1 minutes and biological t½ of ∼<½ hour4, 6-9, 12 and 13. In patients with volume overload, including those with CHF, circulating natriuretic peptides are elevated. This is thought to be indicative of a compensatory mechanism attempting to reinstate homeostasis. However, in severe congestion, it appears that the body is unable to produce sufficient quantities to restore balance.
- The present applicant has now recognised that the benefits demonstrated in preclinical and clinical use of VDSL in the treatment of CHF are superior to those seen with the current natriuretic treatments for ADCHF14, and hereby proposes VSDL administration to patients with chronic CHF or ADCHF as a safe and effective treatment for mediating beneficial haemodynamic effects with additional beneficial natriuretic, diuretic and renal effects, whilst regulating plasma volume and blood pressure (BP) within clinically acceptable ranges and without seriously adverse side effects. It is also anticipated that such VSDL treatment may reduce hospitalisation time and readmission rates for chronic CHF and ADCHF patients. Further, the present applicant has found that effective treatment of chronic CHF and ADCHF patients with VSDL can be achieved with doses that are substantially lower than expected.
- In its broadest aspect, the present invention is directed to vessel dilator (VSDL) for use in treating acute decompensated congestive heart failure (ADCHF) in a subject. Preferably, the VSDL is administered to the subject at an effective amount by infusion at a rate of 1 to 400 ng per kg subject body weight per minute (ng/kg/min).
- The subject may be a non-human primate or other mammalsuch as livestock (including race horses), an exotic animal (e.g. tigers and elephants) or a companion animals (e.g. dogs and cats), however typically the subject will be a human, in which case, VSDL is most preferably used for treating ADCHF characterised by:
- 1. Dyspnoea at rest or dyspnoea with minimal activity (ie difficulty breathing at rest while sitting, or difficulty breathing while lying flat or with one pillow, or difficulty breathing with minimal activity such as talking, eating); and
- 2. At least one of the following signs:
- Tachypnoea with respiratory rate > 20 breaths per minute, or
- Pulmonary congestion/oedema with rales or crackles/crepitations at least a third above lung bases; and
- 3. At least one of the following objective measures:
- Pulmonary oedema/congestions as shown by chest X-ray, or
- Circulating B-type natriuretic peptide (BNP) concentration of ≥ 400 pg/ml or circulating NT-proBNP concentration of ≥ 1000 pg/ml, or
- A PCWP > 20 mmHg or
- A systolic dysfunction within the last 12 months (EF < 50%) as determined by Trans-Thoracic Echocardiogram (TTE), nuclear testing, cardiac magnetic resonance imaging (MRI) or ventricular angiography).
- The term "effective amount" as used herein refers to an amount of the VSDL that will elicit a desired biological or therapeutic response in the subject (e.g. beneficial haemodynamic effects with, preferably, additional beneficial natriuretic, diuretic and renal effects whilst regulating plasma volume and blood pressure (BP) within clinically acceptable ranges). The effective amount will, however, typically be in the range of 0.1 to 75 µg/kg/day. The effective amount of VSDL is preferably administered by infusion (preferably, by intravenous (iv) or subcutaneous (sc) infusion) as a single dose per day or, otherwise, across multiple times per day (eg 2 to 4 times per day). The effective amount of VSDL may, for example, be administered by infusion at a rate of < 100 ng/kg/min, and preferably, at a rate of about ≤ 75 ng/kg/min, more preferably at a rate of about ≤ 50 ng/kg/min or
≤ 30 ng/kg/min, still more preferably at a rate of about ≤ 25 ng/kg/min, even still more preferably ≤ 20 ng/kg/min and, and yet still more preferably, at a rate of about ≤ 15 ng/kg/min. -
-
Figure 1 provides tabulated response data for three ADCHF patients infused intravenously (iv) with 12.5 ng/kg/min for 60 minutes recorded from commencement of infusion (0 minutes) to 5 days post-infusion as indicated; -
Figure 2 provides graphical representations of the results ofFigure 1 : (A) Mean arterial pressure (MAP), (B) Pulmonary capillary wedge pressure (PCWP), (C) Cardiac index (CI), (D) Systemic vascular resistance (SVR), and NT-proBNP circulatory levels (ng/L); and -
Figure 3 provides a graphical representation of measured VSDL concentrations in blood samples taken at the various time points, as corrected for a baseline (ie endogenous) VSDL concentration of 0.024 ng/ml. - The present invention relates to vessel dilator (VSDL), a peptide derived from atrial natriuretic peptide (ANP) prohormone, for use in treating ADCHF in a subject. Preferably, the VSDL is administered to a subject at an effective amount, typically in the range of 0.1 to 75 µg/kg/day.
- In a preferred embodiment, the VSDL is administered to the subject an effective amount by infusion at a rate of 1 to 400 ng per kg subject body weight per minute (ng/kg/min).
- In a preferred embodiment, the effective amount of VSDL is in the range of 0.1 to 75 µg/kg/day, more preferably in the range of about 0.1 to 25 µg/kg/day, still more preferably in the range of about 0.1 to 20 µg/kg/day or about 0.1 to 5 µg/kg/day, and even still more preferably, in the range of about 0.1 to 3.5 µg/kg/day or 0.1 to 1.5 µg/kg/day. Most preferably, the effective amount that is administered to the subject will be about 0.75 µg/kg/day.
- The effective amount of VSDL may, for example, be administered by infusion at a rate of < 100 ng/kg/min, and preferably, at a rate of about ≤ 75 ng/kg/min, more preferably at a rate of about ≤ 50 ng/kg/min or ≤ 30 ng/kg/min, still more preferably at a rate of about ≤ 25 ng/kg/min, even still more preferably ≤ 20 ng/kg/min and, and yet still more preferably, at a rate of about ≤ 15 ng/kg/min. Most preferably, the effective amount is infused at a rate in the range of 1 to 15 ng/kg/min, most preferably at a rate of about 12.5 ng/kg/min.
- The effective amount of VSDL may be infused (preferably, by intravenous (iv) or subcutaneous (sc) infusion) as a single dose per day or, otherwise, across multiple times per day (e.g. as three equal separate doses at 0 hours, 6 hours and 12 hours).
- Typically, a single dose (or each dose of a multidose regimen), will be infused over a period of about 60 minutes.
- Where the rate of the infusion is at a preferred rate of ≤ 75 ng/kg/min, it is considered that a single dose over a period of about 60 minutes will provide an effective daily dose (ie of ≤ 4.5 µg/kg/day). Further, where lower infusion rates are employed of 25 ng/kg/min and 12.5 ng/kg/min, it is considered that a single dose over a period of 60 minutes will provide an effective daily dose of ≤ 1.5 µg/kg/day and ≤ 0.75 µg/kg/day, respectively.
- Preferably, VSDL is used for treating ADCHF with a symptom severity level of NYHA class III or IV. Most preferably, VSDL is used for treating ADCHF in a human characterised by:
- 1. Dyspnoea at rest or dyspnoea with minimal activity (ie difficulty breathing at rest while sitting, or difficulty breathing while lying flat or with one pillow, or difficulty breathing with minimal activity such as talking, eating); and
- 2. At least one of the following signs:
- Tachypnoea with respiratory rate > 20 breaths per minute, or
- Pulmonary congestion/oedema with rales or crackles/crepitations at least a third above lung bases; and
- 3. At least one of the following objective measures:
- Pulmonary oedema/congestions as shown by chest X-ray, or
- Circulating B-type natriuretic peptide (BNP) concentration of ≥ 400 pg/ml or circulating NT-proBNP concentration of ≥ 1000 pg/ml, or
- A PCWP > 20 mmHg or
- A systolic dysfunction within the last 12 months (EF < 50%) as determined by Trans-Thoracic Echocardiogram (TTE), nuclear testing, cardiac magnetic resonance imaging (MRI) or ventricular angiography).
-
- Other suitable VSDL peptides include:
- Pongo pygmaeus (common orang-utan)
- Macaca mulatta (rhesus monkey) and
- Felis catus
- Peptides derived from ANP prohormone may be produced by any of the standard protein synthesis methods well known to the person skilled in the art or, more preferably, by recombinant techniques involving, for example, the introduction of a polynucleotide molecule encoding the particular peptide into a suitable host cell (eg a host cell selected from bacterial cells such as E. coli, Streptomyces and S. typhimurium; fungal cells such as yeast cells; insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as Chinese hamster ovary (CHO), monkey kidney (COS) cells and human embryonic kidney 293 (HEK 293) cells; and plant cells) and culturing the cell under conditions suitable for the expression of the particular peptide.
- Preferably, the VSDL peptide derived from ANP prohormone will be administered as a composition consisting of a simple solution or suspension of the peptide in a pharmaceutically-acceptable carrier. However, it will be readily appreciated by the person skilled in the art, that the peptide may be bound or associated with a carrier molecule (eg a carrier protein or fusion partner such as human serum albumin (HSA) or a polysaccharide (eg Dextran) or polyether (eg polyethylene glycol)) in order to modulate the biological activity and/or serum half-life time of the peptide or mimetic.
- The term "pharmaceutically-acceptable carrier" as used herein refers to any pharmaceutically- or veterinary-acceptable solvent, suspending agent or vehicle for delivering the peptide derived from ANP prohormone or mimetic thereof to the subject. The carrier may include one or more pharmaceutical additives of a type appropriate to, for example, iv administration (eg excipients, preservatives, stabilisers etc).
- The VSDL peptide derived from ANP prohormone may be administered to the subject in a combination therapy. However, while it is considered that the administration of VSDL should not cause clinically significant hypotension, they can be vasodilatory and, therefore, it is preferred that any combination therapy avoids other vasodilatory agents which may cause a synergetic blood pressure lowering. For that reason, the present invention may not be suitable for the treatment of subjects already using vasodilatory agents.
- The administration of the VSDL peptide by infusion is, preferably, achieved intravenously (iv) (which is particularly suitable in the hospital setting) or subcutaneously (sc) (which is suitable for both hospitalised patient and out-of-hospital administration). For example, infusion may be via a standard catheter or implantable drug port (eg a Port-a-Cath®; Smiths Medical MD, Inc., St. Paul MN, United States of America), or otherwise achieved using a drug infusion pump (eg implantable drug infusion pumps such as an Alzet® osmotic pump (Durect Corporation, Cupertino CA, United States of America) and a Duros® device (Intarcia Therapeutics, Inc., Hayward CA, United States of America), or a drug infusion pump for subcutaneous (sc) administration such as a Paradigm™ device (Medtronic Australasia Pty Ltd, Gladesville NSW, Australia) all of which can provide a controlled release of the peptide) which preferably infuses the peptide at a constant rate.
- The use of an implantable drug port or drug infusion pump will be particularly well suited for long term treatment. Typically, the peptide will be infused at a constant rate, however, in some cases it may be desirable to employ a drug infusion pump employing a feedback control mechanism (eg a feedback linked to measurement of oedema (in the lung) or other surrogate marker) to control release of the peptide.
- In one particularly preferred embodiment, the VSDL is administered to the subject at an effective amount, wherein said effective amount is in the range of about 0.1 to 20 µg/kg/day and is administered by infusion, preferably intravenous (iv) or subcutaneous (sc) infusion, at a rate of ≤ 50 ng/kg/min.
- In another particularly preferred embodiment, the VSDL is administered to the subject at an effective amount, wherein said effective amount is in the range of about 0.1 to 1.5 µg/kg/day and is administered by infusion, preferably intravenous (iv) or subcutaneous (sc) infusion.
- It will be appreciated by the person skilled in the art that the effective amount and frequency of administration of the peptide for any particular subject may be varied and will depend upon a variety of factors including the activity of the particular peptide that is utilised, the metabolic stability and length of action of the particular peptide, the age, body weight, general health, sex and diet of the particular subject, and the time of administration, rate of excretion, drug combination and severity of the ADCHF being treated.
- The present invention is hereinafter further described by way of the following, non-limiting example(s).
- This example describes a study to examine whether VSDL administration to ADCHF patients will be safe and induce improvements in haemodynamic parameters, as well as renal, natriuretic and diuretic parameters, whilst regulating plasma volume and BP within clinically acceptable ranges and without seriously adverse side effects.
- VSDL in the form of a white lyophilised powder (synthesised using standard protein synthesis method by Auspep Pty Ltd, Parkville, VIC, Australia), stored in an ultra low freezer (-80°C), was reconstituted in a vial with 10 ml of 0.9% saline (preservative free) and aseptically transferred into a 20 ml syringe (that conects to a patient cannula) before use.
- Initially, an iv dose of 12.5 ng/kg/min was infused into test subjects for 60 minutes with a syringe driver (Alaris Asena GS syringe driver; CareFusion Corporation, San Diego, CA, United States of America). This "safety dose" was chosen merely to trial the subjects for any adverse effects. Subsequently, a dose of 25 ng/kg/min (as infused for 60 minutes) was trialled. Additionally, a trial will be conducted with a dose of 50 ng/kg/min (for 60 minutes).
- Test adult subjects, both male and female, showing either acute exacerbations of chronic CHF or ADCHF (ie in individuals who had not previously shown heart failure), were recruited for the study. The following inclusion and exclusion criteria were applied:
- In order to be eligible, a subject must have chronic CHF or ADCHF (NYHA class III - NYHA class IV) defined as:
- 1. Showing dyspnoea at rest or dyspnoea with minimal activity (ie difficulty breathing at rest while sitting, or difficulty breathing while lying flat or with one pillow, or difficulty breathing with minimal activity such as talking, eating); AND
- 2. Showing at least one of the following signs:
- Tachypnoea with respiratory rate > 20 breaths per minute, OR
- Pulmonary congestion/oedema with rales or crackles/crepitations at least a third above lung bases; AND
- 3. At least one of the following objective measures:
- Showing, by chest X-ray, pulmonary oedema/congestions OR
- Circulating B-type natriuretic peptide (BNP) concentration of ≥ 400 pg/ml or circulating NT-proBNP concentration of ≥ 1000pg/ml at presentation, OR
- PCWP > 20 mmHg OR
- Showing systolic dysfunction within the last 12 months (EF < 50%) as determined by TTE, nuclear testing, cardiac MRI or ventricular angiography);
- 4. Male and/or female, 18 years or older; and
- 5. If a woman of child bearing potential, testing negative to β-hCG.
-
- 1. Evidence in the ED for Myocardial Infarction (MI) or high risk acute coronary syndrome within past 6 weeks, as determined by creatinine kinase (CK) / creatinine kinase muscle-brain isoenzyme (CK-MB) ≥ 2 times upper limit of normal or elevation of Troponin T at baseline >0.1 or as determined by Trans-Thoracic electrocardiogram (TTE);
- 2. Hypotension (SBP < 90 mmHg), cardiogenic shock, volume depletion;
- 3. Persistent, uncontrolled hypertension (SBP >180 mm Hg);
- 4. Subjects with the presence of any CMR contra-indication (including PPM, cerebral aneurysm clips or non-MRI approved metallic implant) are excluded from any MRI study component only;
- 5. Congenital heart defects (including Ventricular Septal Defect, Atrial Septal Defect, Patent Ductus Arteriosus, Tetralogy of Fallot, and Tricuspid Atresia);
- 6. Cardiac surgery within past 4 weeks;
- 7. Diastolic heart failure (preserved left ventricular function - determined by known history, ie E:E prime ratio > 15);
- 8. Severe valvular heart disease: Aortic Stenosis <1.0 cm2, any Idiopathic hypertrophic subaortic stenosis or Hypertrophic Obstructive Cardiomyopathy, acute
Aortic Regurgitation grade Mitral Regurgitation grade - 9. History of cerebrovascular accident (within past 4 weeks) as determined by MRI or Computerised Tomography (CT) Scan;
- 10. Acute or chronic active infection, including pneumonia and urinary tract infection documented by appropriate culture result;
- 11. Very significant renal impairment as determined by a creatinine clearance of < 20 ml/min; and
- 12. Prior participation in any other clinical trial within past 30 days, including present day.
- Three subjects were provided with a single dose of VSDL of 12.5 ng/kg/min for 60 minutes (ie single dose regimen) for a daily dose of 0.75 µg/kg. Subsequently, a further subject was trialled with a single dose of VSDL of 25 ng/kg/min for 60 minutes (to achieve a daily dosage of 1.5 µg/kg). Two further subjects are/have been recruited for trials with a single dose of VSDL of 25 ng/kg/min for 60 minutes, along with another subject (in a preliminary trial) for dosing with a single infusion of VSDL of 50 ng/kg/min for 60 minutes (to achieve a dosage of 3 µg/kg). The results will be compared with subjects recruited as a control group and who will receive a standard method of care for the treatment of ADCHF.
- Treated subjects were assessed by independent reviewers.
- Markers of efficacy were measured at baseline (prior to VSDL infusion), 1 hour (post VSDL infusion), and 24 hours. The markers included CI, PCWP, pulmonary arterial wedge pressure (PAWP), BP, SVR and PVR, and were measured using standard methods well known to the person skilled in the art. Troponin T, proBNP, CK and CK-MB concentrations were also measured by standard methods.
- Secondary efficacy variables that were measured included: dyspnea relief, and increased urine flow and volume output.
- The results shown by subjects treated with a single VSDL dose of 12.5 ng/kg/min for 60 mins are provided in
Figures 1 and2 and summarised in Table 1. The reviewers confirmed that they saw no safety risks. - The results shown by a subject treated with a single VSDL dose of 25 ng/kg/min for 60 mins are provided in Table 2. There were marked beneficial effects; in particular, decreasing dyspnea (ie from 3+ to 1+), increased CI, decreased systemic vascular resistance (SVR) and peripheral vascular resistance (PVR), and decreased PAWP. The infusion was well tolerated and no side effects were observed. The reviewers confirmed that they saw no safety risks.
Table 1 Subject # 1Subject # 2Subject # 3Summary of observations This male subject received a single dose of iv VSDL in saline (12.5 ng/kg/min for 60 mins), on 28 August 2010. The subject tolerated the infusion and was uncompromised during and post infusion. The subject responded during the infusion with an increase in cardiac index (CI), a drop in pulmonary capillary wedge pressure (PCWP), and an asymptomatic drop in blood pressure (BP). This male subject received a single dose of iv VSDL in saline (12.5 ng/kg/min for 60 mins), on 1 September 2010. The infusion was well tolerated by the subject. There was marked diuresis in the first 30 mins following infusion and dyspnea disappeared within 1 hour of starting infusion. There was no significant change in CI, PCWP or mean BP. However, SVR decreased 25% in the first 30 mins of the infusion; the VSDL therefore caused beneficial effects in the treatment of acute heart failure in this subject with global dyskinesis and no side-effects. The subject remained stable during the 24 hours following the infusion. This female subject received a single dose of iv VSDL in saline (12.5 ng/kg/min for 60 mins), on 7 October 2010. The subject tolerated the infusion well. There was an increase in CI, a fall in PCWP, and an asymptomatic drop in BP. It also appeared that SVR was improved. Further, the blood concentration of the CHF marker proBNP, decreased 75% during and within the 24 hours following the infusion. The subject also remained clinically stable during this period. Table 2 Baseline 24 hrs post-infusion CI 2.26 L/min/m2 2.34 L/min/m2 PAWP 22 mmHg 6 mmHg Arterial BP (mean) 124 mmHg 96 mmHg Urinary Output 2170 ml Troponin T < 0.02 µg/L < 0.02 µg/L CK 188 U/L 156 U/L CK-MB 2.0 µg/L 1.3 µg/L - Since it was thought that subjects suffering significant CHF are unable to produce adequate endogenous amounts of natriuretic peptides to compensate for congestion, the present applicant had selected doses of exogenous VSDL infusion of 50 ng/kg/min, 100 ng/kg/min and 200 ng/kg/min for 60 minutes to ascertain the approximate amounts of exogenous VSDL required by late NHYA class III - NYHA class IV patients to reinstate homeostasis. Such doses were expected to result in an approximately 2-fold, 4-fold and 8-fold increase in total circulating VSDL, respectively. Further, the present applicant had particularly proposed an exogenous dose of VSDL at < 100 ng/kg/min (for 60 mins) for the treatment of chronic CHF or ADCHF as a safe and effective dosage, since it has been identified that the release rate from the heart of VSDL with physiological stimuli is about 138 ng/kg body weight per minute16 and similar dosages have been previously observed to cause a marked natriuresis and diuresis in healthy humans17,18 and, also, improved haemodynamic and renal parameters in persons with stable NYHA class III chronic CHF10. The molar equivalent of the 100 ng/kg body weight dose (for 60 mins) is 26 pmol/kg body weight (for 60 mins). However, in the preliminary trials described above, it was surprisingly found that beneficial effects for the treatment of chronic CHF can be achieved at doses that are much less than 100 ng/kg/min for 60 mins. In particular, at 12.5 ng/kg/min (for 60 mins) and 25 ng/kg/min (for 60 mins). One reviewer commented in respect of
Subject # 3 given 12.5 ng/kg/min (for 60 mins), that the observed 75% drop in the concentration of proBNP (a CHF marker) within 24 hours of the infusion was "truly spectacular". - Following the surprising finding that beneficial effects for the treatment of chronic CHF can be achieved with doses that are much less than that which had been proposed, a study was undertaken to estimate the baseline levels of VSDL and Cmax (ie the peak VSDL concentration that is achieved) following infusion.
- Cmax was estimated from blood samples of a CHF patient (NYHA class III) taken at 30 mins, 1 hr, 1.5 hr, 2 hr, 3 hr, 4 hr, 5 hr, 6 hr and 12 hr following infusion, using a proprietary method (CPR Pharma Services Pty Ltd, Thebarton, SA, Australia) involving mass spectroscopy. The baseline VSDL concentration (ie endogenous level) was estimated from an identical sample taken prior to infusion (ie "predose").
- The baseline VSDL concentration was estimated as 0.024 ng/ml. The measured VSDL concentrations in the samples taken at the various time points are shown in Table 3 and
Figure 3 . A corrected concentration, which accounts for the baseline concentration is also shown; however due to the low level of the baseline concentration, the corrected concentrations vary little from the actual, measured concentrations. - The Cmax was therefore 4.376 ng/ml (~4.4 ng/ml) achieved 30 mins (ie Tmax of 0.5 hr) after infusion. This value was also estimated after 1 hr. There is a slight curve to the measured VSDL concentration profile (
Figure 3 ) indicating that the elimination of VSDL from the blood stream does not clearly follow first order kinetics. Using the values shown in Table 3 to estimate the terminal elimination rate, the LOQ of 0.2 ng/ml gives an estimated half-life (t½) of 20 minutes, while using the point just below the LOQ estimates a slightly longer half-life of 25-30 minutes, excluding and including the Cmax values, respectively.Table 3 Time point (hrs) Corrected Concentration (ng/ml) Concentration (ng/ml) 0.5 4.376 4.4 1 4.376 4.4 1.5 1.176 1.2 2 0.556 0.58 3 0.136 0.16 4 0.061 0.085 5 0.022 0.046 6 0.005 0.029 12 0.018 0.042 Predose 0.024 0.024 - The baseline VSDL concentration in blood was estimated as 0.024 ng/ml. This was surprisingly low given previously published reports of endogenous basal levels of circulating VSDL in patients with varying degrees of CHF; for example, a basal VSDL concentration of 3412 ± 546 (SEM) fmol/ml has been reported for CHF NYHA class III patients and 7691 ± 1344 (SEM) fmol/ml for CHF NYHA class IV patients6. These values correspond to about 13.23 ng/ml and 29.82 ng/ml. Cmax for the infused VSDL was achieved at a Tmax of 0.5 hr. Further, the t½ of 25-30 mins estimated from this study is much shorter than that previously reported (ie 120 mins). While not wishing to be bound by theory, it is considered that this previously reported t½ of 120 mins may have been the result of inadvertently providing a supramaximal dose.
- The surprising finding that effective treatment of chronic CHF or ADCHF patients with VSDL can be achieved with doses that are substantially lower than expected, is likely to have important implications in Chronic CHF and ADCHF treatment including, for example, avoidance of seriously adverse side effects as well as allowing treatment of patients with significant renal impairment (eg having a creatinine clearance of 20 to 60 ml/min) whom might otherwise may not have been regarded as treatable.
- Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
-
- 1. Heart Disease and Stroke Statistics-2003 update. Dallas: American Heart Association 2002.
- 2. Heywood JT, Heart Fail Rev 9:195-201 (2004).
- 3. Fonarow G, Heart Fail Rev 9:179-185 (2004).
- 4. Vesely DL, Am J Physiology 285:F167-F177 (2003).
- 5. Habibullah AA et al., Clin Exp Pharmacol Physiol 22:130-135 (1995).
- 6. Winters CJ et al., Circulation 80:438-449 (1989).
- 7. Vesely DL et al., Proc Soc Exp Biol Med 192:230-235 (1989).
- 8. Hunter EFM et al., Scan J Clin Lab Invest 58:205-216 (1998).
- 9. Franz M et al., Kidney Int 58:374-378 (2000).
- 10. Vesely DL et al., Circulation 98:323-329 (1998).
- 11. Vesely DL et al., Life Sci 66(10):905-913 (2000).
- 12. De Palo EF et al., Clin Chem 46:843-847 (2000).
- 13. Franz M et al., Kidney Int 59:1928-1934 (2001).
- 14. Peacock WF and MD Emerman, Heart Failure Reviews 9:187-193 (2004).
- 15. Kirshenbaum K et al., Curr Opin Struct Biol 9:530-535 (1999).
- 16. Vesely DL et al., J Clin Endocrinol Metab 78:1128-1134 (1994).
- 17. Vesely DL et al., Circulation 90:1129-1140 (1994).
- 18. Vesely DL et al., Peptides 11:193-197 (1990).
- 19. Fonarow GC et al., Arch Intern Med 168(8):847-854 (2008).
-
- <110> Madeleine Pharmaceuticals Pty Ltd
- <120> THERAPEUTIC METHOD FOR TREATING CONGESTIVE HEART FAILURE
- <130> 36263PCT
- <160> 4
- <170> PatentIn version 3.5
- <210> 1
<211> 37
<212> PRT
<213> Homo sapiens - <400> 1
- <210> 2
<211> 37
<212> PRT
<213> Pongo pygmaeus - <400> 2
- <210> 3
<211> 37
<212> PRT
<213> Macaca mulatta - <400> 3
- <210> 4
<211> 37
<212> PRT
<213> Felis catus - <400> 4
Claims (11)
- Vessel dilator (VSDL) for use in treating acute decompensated congestive heart failure (ADCHF) in a subject.
- The vessel dilator for use of claim 1, wherein the VSDL is administered to the subject at an effective amount by infusion at a rate of 1 to 400 ng per kg subject body weight per minute (ng/kg/min).
- The vessel dilator for use of claim 2, wherein the effective amount of the VSDL is in the range of 0.1 to 75 µg/kg/day.
- The vessel dilator for use of claim 1, wherein the VSDL is administered to the subject at an effective amount in the range of about 0.1 to 20 µg/kg/day infusion at a rate of ≤ 50 ng/kg/min.
- The vessel dilator for use of claim 1, wherein the VSDL is administered to the subject at an effective amount in the range of about 0.1 to 1.5 µg/kg/day and is administered by infusion.
- The vessel dilator for use of claim 1, wherein the VSDL is administered to the subject at an effective amount in the range of about 0.1 to 5 µg/kg/day.
- The vessel dilator for use of claim 6, wherein the effective amount of the VSDL is in the range of about 0.1 to 3.5 µg/kg/day.
- The vessel dilator for use of claim 6 or 7, wherein the VSDL is administered by infusion at a rate of ≤ 50 ng/kg/min.
- The vessel dilator for use of claim 8, wherein the VSDL is administered by infusion at a rate in the range of 1 to 15 ng/kg/min.
- The vessel dilator for use of any one of the preceding claims, wherein the VSDL is administered to the subject at an effective amount as a single daily dose by infusion over a period of about 60 minutes.
- The vessel dilator for use of any one of the preceding claims, wherein the VSDL consists of the amino acid sequence shown as SEQ ID NO: 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161445826P | 2011-02-23 | 2011-02-23 | |
US201161445814P | 2011-02-23 | 2011-02-23 | |
PCT/AU2011/001026 WO2012019237A1 (en) | 2010-08-12 | 2011-08-11 | Therapeutic method for treating congestive heart failure |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2678025A1 EP2678025A1 (en) | 2014-01-01 |
EP2678025A4 EP2678025A4 (en) | 2014-07-23 |
EP2678025B1 true EP2678025B1 (en) | 2017-03-08 |
Family
ID=48431014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11815913.6A Active EP2678025B1 (en) | 2011-02-23 | 2011-08-11 | Vsdl for use in the treatment of acute decompensated congestive heart failure |
Country Status (6)
Country | Link |
---|---|
US (1) | US20150174201A1 (en) |
EP (1) | EP2678025B1 (en) |
JP (1) | JP5850953B2 (en) |
CN (1) | CN103402534B (en) |
AU (1) | AU2011288919B2 (en) |
SG (1) | SG192744A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3056433A1 (en) * | 2017-03-22 | 2018-09-27 | Pharmain Corporation | Npra agonists, compositions, and uses thereof |
GB202000945D0 (en) * | 2020-01-22 | 2020-03-04 | Univ Oslo | Treatment of cardiac remodelling |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5691310A (en) * | 1987-09-29 | 1997-11-25 | Vesely; David L. | Methods of treatment using proANF peptides |
WO2004011498A2 (en) * | 2002-07-31 | 2004-02-05 | Conjuchem Inc. | Long lasting natriuretic peptide derivatives |
CN101505784B (en) * | 2006-03-30 | 2013-08-21 | 帕拉丁科技公司 | Cyclic natriuretic peptide constructs |
-
2011
- 2011-08-11 SG SG2013061346A patent/SG192744A1/en unknown
- 2011-08-11 EP EP11815913.6A patent/EP2678025B1/en active Active
- 2011-08-11 JP JP2013554747A patent/JP5850953B2/en not_active Expired - Fee Related
- 2011-08-11 AU AU2011288919A patent/AU2011288919B2/en not_active Ceased
- 2011-08-11 CN CN201180068456.6A patent/CN103402534B/en active Active
-
2014
- 2014-12-18 US US14/575,606 patent/US20150174201A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
US20150174201A1 (en) | 2015-06-25 |
AU2011288919A1 (en) | 2013-05-02 |
CN103402534B (en) | 2016-10-12 |
AU2011288919B2 (en) | 2013-10-31 |
CN103402534A (en) | 2013-11-20 |
JP2014506584A (en) | 2014-03-17 |
EP2678025A4 (en) | 2014-07-23 |
JP5850953B2 (en) | 2016-02-03 |
SG192744A1 (en) | 2013-09-30 |
EP2678025A1 (en) | 2014-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9018168B2 (en) | Therapeutic method for treating congestive heart failure | |
US20160324930A1 (en) | Systems and methods for therapy of kidney disease and/or heart failure using chimeric natriuretic peptides | |
RU2768283C2 (en) | Semaglutide in cardiovascular conditions | |
EP3318267B1 (en) | Hunter syndrome therapeutic agent | |
WO2012115772A2 (en) | Therapy for kidney disease and/or heart failure | |
WO2003079979A2 (en) | Method for treating congestive heart failure | |
EP1919491B1 (en) | Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure | |
JPH11505265A (en) | Administration of IGF-I | |
EP2678025B1 (en) | Vsdl for use in the treatment of acute decompensated congestive heart failure | |
US7112560B2 (en) | Angiogenically effective unit dose of FGF-2 and method of use | |
US10004754B2 (en) | ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment | |
CN115335073A (en) | Combination therapy comprising GLP-1 and/or GLP-1 analogs, and insulin and/or insulin analogs | |
JP2019535791A (en) | Insulin degludec for improved glycemic control and reduction of acute and long-term diabetic complications | |
EP2123292B1 (en) | Angiogenically effective unit dose of FGF-2 and method of use | |
US20160303199A1 (en) | Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound | |
AU2014100081A4 (en) | Therapeutic method for treating congestive heart failure | |
US20150038418A1 (en) | Natriuretic peptide compositions and methods of preparation | |
EP3996679B1 (en) | High concentration insulin formulation | |
AU2023240415A1 (en) | Use of follistatin-like 1 (fstl1) in cardiometabolic heart failure | |
JP2021528424A (en) | Methods and Uses to Control Postprandial Glucose Levels in Subjects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130820 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20140623 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61M 5/14 20060101ALI20140616BHEP Ipc: A61K 38/16 20060101AFI20140616BHEP Ipc: A61M 5/178 20060101ALI20140616BHEP Ipc: A61P 9/04 20060101ALI20140616BHEP Ipc: A61K 38/22 20060101ALI20140616BHEP Ipc: A61M 5/142 20060101ALI20140616BHEP |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GEIMER, THOMAS, ROBERT |
|
17Q | First examination report despatched |
Effective date: 20151209 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20161005 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MADELEINE PHARMACEUTICALS PTY LTD |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 872922 Country of ref document: AT Kind code of ref document: T Effective date: 20170315 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602011035789 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20170308 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170609 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170608 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 872922 Country of ref document: AT Kind code of ref document: T Effective date: 20170308 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170608 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170708 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170710 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602011035789 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 |
|
26N | No opposition filed |
Effective date: 20171211 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20170831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170811 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170811 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170811 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20110811 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170308 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170308 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240207 Year of fee payment: 13 Ref country code: GB Payment date: 20240202 Year of fee payment: 13 Ref country code: CH Payment date: 20240214 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240208 Year of fee payment: 13 |